Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PEG-ELECTROLYTES

2 general benefit · 1 not a benefit

JampLyte · DIN 02378329 · · Pd-4L Pk

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
JampLyte · DIN 02378329 Manufacturer: Jamp Pharma Corporation; listing date 2026-06-30 Health Canada: Marketed since 2025-06-17 · brand JAMPLYTE · ATC A06AD65 MACROGOL, COMBINATIONS · form Powder · route Oral · ingredients POLYETHYLENE GLYCOL 3350 238.2 G/280G, SODIUM SULFATE 22.96 G/280G, SODIUM BICARBONATE 6.76 G/280G, SODIUM CHLORIDE 5.84 G/280G, POTASSIUM CHLORIDE 3.04 G/280G · company Jamp pharma corporation · schedule Ethical
Check this DIN again · Health Canada product record

JampLyte: Formulary list price $16.4640/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.4640 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86414 · Verify on the e-Formulary ↗ (DIN 02378329)

Source record
DIN 02378329: JampLyte Raw flags: sec3=Y Item: 401200040; group id 549; item number 1481; lccId None; manufacturer id JPC Source form: Pd-4L Pk; strength: None Recorded listing: General benefit Source prices (unrounded): $16.4640; ministry $16.4640 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02378329 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86414
Interchangeable products
Colyte · DIN 00677442 · not recorded PegLyte Powder · DIN 00777838 · $16.4640
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02378329
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PegLyte Powder · DIN 00777838 · · Pd-4L Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PegLyte Powder · DIN 00777838 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 2013-05-22 · brand PEGLYTE POWDER · ATC A06AD10 MINERAL SALTS IN COMBINATION · form Powder for solution · route Oral · ingredients MACROGOL 238.18 G/BOTTLE, SODIUM CHLORIDE 5.85 G/BOTTLE, SODIUM SULFATE 22.96 G/BOTTLE, POTASSIUM CHLORIDE 3.05 G/BOTTLE, SODIUM BICARBONATE 6.76 G/BOTTLE · company Pendopharm division of pharmascience inc · schedule Ethical
Check this DIN again · Health Canada product record

PegLyte Powder: Formulary list price $16.4640/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.4640 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9351 · Verify on the e-Formulary ↗ (DIN 00777838)

Source record
DIN 00777838: PegLyte Powder Raw flags: sec3=Y Item: 401200040; group id 549; item number 1481; lccId None; manufacturer id PEN Source form: Pd-4L Pk; strength: None Recorded listing: General benefit Source prices (unrounded): $16.4640; ministry $16.4640 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00777838 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9351
Interchangeable products
Colyte · DIN 00677442 · not recorded JampLyte · DIN 02378329 · $16.4640
Shortage status: resolved shortage (ended 2022-01-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00777838
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Colyte · DIN 00677442 · · Pd-4L Pk

Listed, not a benefitMarketed · checked 2026-09-20
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Colyte · DIN 00677442 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 2013-04-01 · brand COLYTE · ATC A06AD65 MACROGOL, COMBINATIONS · form Powder for solution · route Nasogastric, Oral · ingredients POLYETHYLENE GLYCOL 3350 857.69 MG/G, SODIUM CHLORIDE 20.87 MG/G, POTASSIUM CHLORIDE 10.65 MG/G, SODIUM BICARBONATE 24.02 MG/G, SODIUM SULFATE 81.2 MG/G · company Skyline products ltd. · schedule Ethical
Check this DIN again · Health Canada product record

Colyte: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6616 · Verify on the e-Formulary ↗ (DIN 00677442)

Source record
DIN 00677442: Colyte Raw flags: notABenefit=Y, sec3=Y Item: 401200040; group id 549; item number 1481; lccId None; manufacturer id PEN Source form: Pd-4L Pk; strength: None Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00677442 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6616
Interchangeable products
JampLyte · DIN 02378329 · $16.4640 PegLyte Powder · DIN 00777838 · $16.4640
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00677442
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (40:12 Replacement Agents) and how they are covered

Matched class: 40:12 Replacement Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ELECTROLYTE & DEXTROSE 40:12 Replacement Agents

ELECTROLYTE & DEXTROSE

· 2 products · General benefit · strengths: · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:12
Full class listing Related classes: 40:18 Potassium-Removing Resins, 40:28 Diuretics, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: constipation
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: BISACODYL BISACODYL · General benefit INDICATIONS AND CLINICAL USE DULCOLAX is indicated for: • Relief of occasional constipation • Under medical supervision, for the preparation of diagnostic procedures, in pre- and postoperative treatment, and in conditions which require defecation to be facilitated. PM: https://pdf.hres.ca/dpd_pm/00076868.PDF; date November 3, 2022; DIN 00003875; fetched 2026-09-10 Product monograph PRUCALOPRIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS RESOTRAN® (prucalopride succinate tablets) is indicated for: • The treatment of chronic idiopathic constipation in adult female patients in whom laxatives failed to provide adequate relief. PM: https://pdf.hres.ca/dpd_pm/00073288.PDF; date NOV 08, 2023; DIN 02377012; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults Colyte® (PEG 3350 and Electrolytes) is indicated for:  bowel cleansing prior to colonoscopy or barium enema x-ray examination or surgical procedures requiring a clean colon.  the treatment of constipation https://pdf.hres.ca/dpd_pm/00061814.PDF PM date: March 25, 2021 Source product: COLYTE; DIN 00677442; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Colyte: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026